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Abstract
Leukotrienes are reported to be potent proinflammatory mediators that play a role in the development of several inflammatory 
diseases such as asthma, rheumatoid arthritis and periodontal disease. Leukotrienes have also been associated with protection 
against infectious diseases. However, the role of leukotrienes in Mycobacterium tuberculosis infection is not understood. To 
answer this question, we studied the role of leukotrienes in the protective immune response conferred by prime-boost heterolo-
gous immunization against tuberculosis. We immunized BALB/c mice (4-11/group) with subcutaneous BCG vaccine (1 x 105 M. 
bovis BCG) (prime) followed by intramuscular DNA-HSP65 vaccine (100 µg) (boost). During the 30 days following the challenge, 
the animals were treated by gavage daily with MK-886 (5 mg·kg-1·day-1) to inhibit leukotriene synthesis. We showed that MK-
886-treated mice were more susceptible to M. tuberculosis infection by counting the number of M. tuberculosis colony-forming 
units in lungs. The histopathological analysis showed an impaired influx of leukocytes to the lungs of MK-886-treated mice 
after infection, confirming the involvement of leukotrienes in the protective immune response against experimental tuberculosis. 
However, prime-boost-immunized mice treated with MK-886 remained protected after challenge with M. tuberculosis, suggesting 
that leukotrienes are not required for the protective effect elicited by immunization. Protection against M. tuberculosis challenge 
achieved by prime-boost immunization in the absence of leukotrienes was accompanied by an increase in IL-17 production in the 
lungs of these animals, as measured by ELISA. Therefore, these data suggest that the production of IL-17 in MK-886-treated, 
immunized mice could contribute to the generation of a protective immune response after infection with M. tuberculosis.
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Tuberculosis (TB) is a disease caused by infection with 
Mycobacterium tuberculosis. The World Health Organiza-
tion estimates that 2-3 million people die from TB each 
year, and one third of the planet’s population is infected 
with the tubercle bacillus. However, almost 90% of those 
infected do not develop the disease. Conditions affecting 
the immune system, such as co-infection with HIV, diabetes 
or malnutrition, increase the risk of developing the active 
form of the disease (1).
Cell-mediated immune responses play a critical role in 
the host’s defense against intracellular pathogens such as 
M. tuberculosis. Protection is associated with the develop-
ment of interferon-gamma (IFN-γ)-producing Th1 CD4+ 
cells, which activate macrophage microbicidal mecha-
nisms against intracellular bacteria. Activated macrophage 
also secretes tumor necrosis factor-alpha (TNF-α) and 
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chemokines, such as monocyte chemotactic protein-1, 
macrophage inflammatory protein-1α (MIP-1α), MIP-1β 
and RANTES (regulated upon activation, normal T cell 
expressed and secreted), which plays a key role in granu-
loma formation (reviewed in Ref. 2). It has been reported 
that cytotoxic CD8+ T cell-mediated killing of infected host 
cells and IFN-γ-producing CD8+ T cells also play a role 
in the defense against M. tuberculosis (3). In addition to 
IFN-γ and cytokines such as interleukin-12 (IL-12) and 
TNF-α (4,5), lipid mediators, such as leukotrienes (LT), 
participate in the host defense against M. tuberculosis 
infection. M. tuberculosis-infected mice treated with the 
inhibitor of LT synthesis, MK-886, showed an increase in 
lung bacterial burden and a decrease in IFN-γ, IL-12 and 
nitrite secretion. In addition, the influx of neutrophils and 
mononuclear cells to the lungs of MK-886-treated mice 
was reduced (6). 
Since LT contribute to IL-12 production, these lipid me-
diators may indirectly participate in CD4+ T differentiation to 
the Th1 pattern. Furthermore, during a secondary immune 
response against infection by Histoplasma capsulatum, 
LT play a role by recruiting memory CD4+ and CD8+ cells 
to the lung (7). The activity of LT as powerful leukotropic 
and proinflammatory mediators involved in host defenses 
in a variety of infectious diseases (6,8,9), including my-
cobacterial infections (6), led us to suggest that LT might 
be involved in the protective immune response generated 
by heterologous prime-boost immunization with Bacille 
Calmette-Guérin (BCG) prime/DNA-HSP65 booster against 
M. tuberculosis infection.
BCG is still the only vaccine available for TB prevention. In 
attempts to develop a new vaccine against TB, some groups 
have focused on developing recombinant antigens, while 
others have concentrated their efforts on the development 
of a recombinant BCG vaccine capable of inducing greater 
protective immunity than conventional BCG (10). A different 
prophylactic vaccination strategy consists of boosting the 
immunogenicity of the BCG vaccine. This strategy is defined 
as prime-boost immunization. Secreted antigens, such as 
Mtb72F, 85A, or 85B antigens, and the 6-kDa early-secretion 
antigen target (ESAT-6) have been shown to be promising 
candidates for BCG-boosting vaccines in mice, guinea pigs, 
and nonhuman primates (11-13). Experimental data collected 
by our group over the last few years have shown that a DNA 
vaccine encoding the M. leprae 65-kDa heat shock protein 
gene (DNA-HSP65) represents a strategy for experimental 
TB prevention (14). In an attempt to optimize the protective 
effect of this DNA vaccine and to boost BCG immunization, 
we found that heterologous prime-boost immunization using 
BCG priming/DNA-HSP65 boosting conferred significant 
protection to challenged mice (15). 
In the present study, we confirmed that LT contribute 
to the protective immune response against M. tubercu-
losis infection in MK-886-treated mice, which were more 
susceptible to M. tuberculosis infection. However, LT were 
not essential in prime-boost vaccinated mice treated with 
MK-886, which remain protected after challenge with M. 
tuberculosis.
Material and Methods 
Mice
Female 6-8-week-old BALB/c mice were obtained from 
the Faculdade de Medicina de Ribeirão Preto (Universidade 
de São Paulo, Brazil). Mice were housed under barrier 
conditions in a level III biohazard laboratory and provided 
with food and sterile water. Experiments were conducted 
according to the Comissão de Ética em Experimentação 
Animal da Faculdade de Medicina de Ribeirão Preto 
(CETEA) ethical guidelines.
Bacteria
M. tuberculosis H37Rv strain (#27294; ATCC, USA) 
was grown for 7 days at 37°C in 7H9 Middlebrook broth 
(Difco, USA) enriched with 0.2% (v/v) glycerol and 10% 
(v/v) oleic acid albumin dextrose (Difco) prepared as previ-
ously described (15). M. bovis BCG (Moreau strain) was 
purchased from Fundação Ataulpho Paiva (FAP), Rio de 
Janeiro, RJ, Brazil.
Plasmid construction
pVAX-HSP65 (DNA-HSP65) vaccine was constructed 
from the pVAX vector (Invitrogen, USA) as described 
(14,15). Endotoxin concentration was determined using 
the Limulus amebocyte lysate kit QCL-1000 (BioWhittaker, 
USA). The amount of endotoxin used for the plasmid in this 
study was ≤0.1 endotoxin units/µg DNA. 
Immunization and challenge infection
For heterologous vaccination, each animal received 1 
x 105 M. bovis BCG in 100 µL phosphate-buffered saline 
(prime) by the subcutaneous route. After 15 days, animals 
received 50 µg DNA-HSP65 in 50 µL saline plus 50% 
sucrose into each quadriceps muscle (booster). Thirty 
days after the last immunization, mice were challenged by 
injection of M. tuberculosis (1 x 105 bacteria/animal) by the 
intratracheal route (15). 
Treatment of mice with MK-886
To inhibit endogenous LT production, animals were 
treated by gavage with the MK-886 compound (Merck 
Frosst, Canada) (5 mg/kg) diluted in 0.5 mL water 1 h prior 
to infection with M. tuberculosis, repeated every 24 h for 30 
days. A dose of 5 mg·kg-1·day-1 has been shown to inhibit 
LT synthesis in a model of pulmonary histoplasmosis (8). 
Control groups were treated with water.
Colony-forming units assay
The lower right and middle lobes of the lungs were 
digested with 0.5 µg/mL Liberase Blendzyme 2 solution 
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(Roche, USA) and 25 U/mL DNAse (Sigma, USA), as 
previously described (14,15). For the colony-forming units 
(CFU) assay, serial dilutions of digested lungs were plated 
onto 7H11 agar medium (Difco Laboratories, USA) and 
CFU number was determined 28 days after incubation at 
37°C.
Cytokine production
The left lobes of the lungs were removed and homog-
enized (Mixer Homogenizer, Labortechnik, Germany) in 2 
mL RPMI 1640 (Sigma), centrifuged at 1500 g and stored 
at -70°C until assayed. IFN-γ and IL-12 concentrations 
were determined in the supernatants by ELISA according 
to manufacturer instructions. The following anti-mouse 
purified monoclonal antibodies (mAb) were used (1 µg/
mL): IFN-γ (R4-6A2) and IL-12 (C15.6; BD Biosciences-
PharMingen, USA). Cytokine-antibody complexes were 
detected via the addition of 0.5 µg/mL of the anti-mouse 
biotinylated mAb IFN-γ (XMG1.2) and IL-12 (C17.8; BD 
Biosciences-PharMingen). For IL-17 detection, ELISA SET 
R&D was used.
Histology
For histopathological analysis, the right upper lobes 
of the lungs were fixed in 10% formalin, embedded and 
processed in paraffin blocks, and then sectioned for light 
microscopy. Five-micron thick sections were stained with 
hematoxylin-eosin. All samples were analyzed by a patholo-
gist in a double-blind assay.
Statistical analysis
All data are reported as means ± SEM. Data were com-
pared using the PRISM software (version 5.0, GraphPad, 
USA). Variables among groups were compared by analysis 
of variance (ANOVA) followed by the Tukey test. Values of 
P < 0.05 were considered to be significant.
Results
LT are not essential for the protection conferred by 
prime-boost immunization
To investigate the role of LT in the protection conferred 
by heterologous BCG/DNA-HSP65 (prime-boost) immu-
nization against M. tuberculosis infection, we evaluated 
the bacterial clearance in the lungs of immunized mice 
treated with MK-886 and challenged with M. tuberculosis in 
comparison to the lungs of non-immunized (saline) infected 
and treated mice. Figure 1B shows that the treatment with 
MK-886 of non-immunized mice increased their suscepti-
bility to infection when compared to water-treated mice (P 
< 0.05). As expected, immunization using the prime-boost 
strategy resulted in a significant reduction in CFU numbers 
in the lungs of water-treated M. tuberculosis-challenged 
mice when compared to the lungs of non-immunized and 
infected mice. However, when compared to animals immu-
nized by prime-boost strategy and treated with MK-886, no 
differences in CFU numbers was observed. These results 
suggest that prime-boost immunization was efficient in 
protecting mice against the M. tuberculosis challenge even 
in the absence of endogenous LT. Taken together, these 
results suggest that LT are important for the immune re-
sponse against TB, but are not an essential component of 
the protective immune response induced after prime-boost 
heterologous immunization.
Regarding the production of cytokines, infected mice 
treated with MK-886 secreted lower concentrations of IFN-γ 
and IL-12 compared to infected mice treated with water (P 
> 0.05; Figure 1C and D, respectively). Prime-boost im-
Figure 1. Effect of the inhibition of endogenous leukotriene (LT) 
synthesis on Mycobacterium tuberculosis growth and cytokine 
production in lungs of prime-boost-immunized, M. tuberculosis-
challenged mice. Animals were immunized by the prime-boost 
(PB) strategy and challenged with 105 M. tuberculosis bacilli 
(Mtb) by intratracheal administration 30 days after the immuni-
zation schedule. Saline-injected animals were used as controls. 
One hour before and every 24 h after infection, animals were 
treated by gavage with water or MK-886 (5 mg·kg-1·day-1) (A). 
Thirty days after challenge, the lung bacterial load was evalu-
ated by colony-forming unit (CFU) counting (B). The production 
of interferon-gamma (IFN-γ) (C), interleukin -12 (IL-12) (D), and 
IL-17 (E) was evaluated in lung homogenates by ELISA. Data are 
reported as means ± SEM (N = 6-11 for CFU counting and 4-9 
for the measurement of cytokines). *P < 0.05 (ANOVA followed 
by the Tukey test).
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munization of water-treated mice reduced IFN-γ and IL-12 
production compared to the respective non-immunized 
group (P < 0.05). There were no significant differences in 
IFN-γ and IL-12 levels between mice immunized by the 
prime-boost strategy and treated with MK-886 and those 
immunized and treated with water (P > 0.05). Moreover, 
immunized, challenged and MK-886-treated mice also se-
creted lower concentrations of IFN-γ and IL-12 compared to 
non-immunized, infected mice treated with MK-886 (Figure 
1C and D). Only those groups immunized by the prime-boost 
strategy and treated with MK-886 showed an increase in 
IL-17 concentrations compared to non-immunized, MK-
886-treated mice (P < 0.05; Figure 1E). 
Inhibition of LT synthesis impaired leukocyte migration 
to the lungs of M. tuberculosis-infected mice
Given the fact that LT were first characterized for their 
role in leukocyte recruitment, we next evaluated inflamma-
tory cell influx to the lungs. Figure 2 shows that infected 
mice (105 M. tuberculosis bacilli) treated with water (Mtb + 
water) had an intense lung parenchyma injury represented 
by diffuse, extensive leukocyte infiltration and bronchus-
associated lymphoid tissue hyperplasia compared to 
uninfected mice. Infected mice treated with MK-886 (Mtb 
+ MK-886) had more visibly preserved lung areas, which 
showed a lower level of leukocyte recruitment than that 
observed in infected, water-treated mice. Lungs of prime-
boost-immunized, water-treated mice (PB + water) also 
showed a reduced cell recruitment compared to lungs of 
non-immunized infected mice (Mtb + water). The lungs of 
prime-boost immunized, MK-886-treated mice (PB + MK-
886) exhibited a considerably lower cell influx in comparison 
to lungs of prime-boost-immunized, water-treated mice. 
These histology results confirm the importance of LT in 
leukocyte recruitment to the lungs during M. tuberculosis 
infection. 
Discussion
In the present study, we confirmed the results of Peres 
et al. (6), who provided evidence for the importance of LT 
in the immune response against M. tuberculosis infection. 
We also confirmed that mice treated with MK-886 were 
more susceptible to M. tuberculosis infection. This higher 
susceptibility was associated with the impaired influx of 
leukocytes to the lungs after infection and with decreased 
concentrations of IFN-γ in the lungs, as previously reported 
by Peres et al. (6). Our results, together with those reported 
by Peres et al. (6), suggest that LT can modulate soluble 
factors related to protection, such as IFN-γ and nitrite, and 
can stimulate the recruitment of leukocytes to the site of 
infection. In a similar manner, treatment of BALB/c mice 
with MK-886 increased their susceptibility to infection 
with H. capsulatum (8). On the other hand, Bafica et al. 
(16) demonstrated that 5-lipoxygenase (5-LO-/-) knockout 
mice were more resistant to M. tuberculosis infection than 
wild-type mice. These investigators attributed the better 
ability of 5-LO-/- mice to control infection to a decreased 
synthesis of lipoxin A4, a 5-LO-derived anti-inflammatory 
mediator (17). However, Peres et al. (6) also showed a 
decrease in the production of lipoxin A4 in MK-886-treated 
infected BALB/c mice. The discrepancy between our results 
and those of Bafica et al. (16) may be related to the differ-
ent route of infection (intratracheal vs aerosol) and to the 
inoculum size (105 bacilli vs 50 or 300 bacilli) because M. 
tuberculosis infection can produce a variety of outcomes, 
including slowly progressive TB or chronic experimental 
disease according to the route of infection, inoculum size 
and mouse strain (18).
Although our results show that LT are related to an ef-
fective immune response against M. tuberculosis infection, 
we found that these lipid mediators do not seem to have 
a key role in the effector immune response induced by a 
prime-boost heterologous vaccination against experimental 
TB. The protection conferred by prime-boost immunization 
Figure 2. Cell influx into the lungs of prime-boost-immunized, My-
cobacterium tuberculosis-challenged mice treated with MK-886. 
Experimental groups were treated, immunized and challenged as 
described in the legend to Figure 1A. Representative HE-stained 
sections of lungs of uninfected mice (control), animals infected 
with M. tuberculosis and treated with MK-886 (Mtb + MK-886) or 
water (Mtb + water), and lungs of animals immunized with prime-
boost (PB), challenged with M. tuberculosis and treated with MK-
886 (PB + MK-886) or with water (PB + water) are shown. Origi-
nal magnification 50X. Bar = 500 µM.
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against a challenge with M. tuberculosis was similar for 
MK-886-treated and -untreated mice. In addition, the lung 
parenchyma from prime-boost-immunized, MK-886-treated 
mice showed better preserved lung areas than that of from 
prime-boost-immunized, untreated mice.
Since we did not observe a significant difference in 
IFN-γ and an increase in IL-17 production in lungs of 
prime-boost-immunized, MK-886-treated mice compared 
to non-immunized, MK-886-treated mice, we suggest that 
the induction of Th17 cells during immunization, and conse-
quently the production of IL-17 by effector and/or memory 
cells during infection, could play a role in the protection 
maintained after treatment with MK-886. IL-17 has been 
described as a potent proinflammatory cytokine, which is 
able to induce recruitment of neutrophils (19). It has been 
recently demonstrated that Th17 cells are essential for the 
protection elicited by a vaccine against TB (ESAT-6 peptide 
mixed with DDA, MPL and TDM adjuvants). The protection 
was based on the production of IL-23, which induced the 
differentiation of Th17 cells. This cell population triggered 
chemokine production with subsequent recruitment of Th1 
cells to the lungs (20). In addition, results from our group also 
suggest that IL-17 is related to protection against experimen-
tal and human TB (Paula MO and Wowk PF, unpublished 
data). These data suggest that prime-boost immunization 
was able to induce differentiation of Th17 cells, and in the 
deficiency in LT synthesis, IL-17 may compensate for the 
low levels of this lipid mediator by contributing to leukocyte 
recruitment for the control of infection. To confirm the role of 
IL-17 in the protection induced by prime-boost immuniza-
tion in LT absence, experiments using IL-17 knockout mice 
remain to be explored. 
Overall, the present results confirm the essential role 
of LT in the immune response against M. tuberculosis. 
Besides, the immunization using the prime-boost strategy 
seems to induce inflammatory mediators, such as IL-17, 
which probably contribute to the protective efficacy, even 
with an inhibition of LT production.
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